Price$26.66+0.04 (+0.15%)
01:30 PM07:45 PM
News · 26 weeks125-36%
2025-10-262026-04-19
Mix7590d
- Insider34(45%)
- Other28(37%)
- SEC Filings4(5%)
- Analyst4(5%)
- Earnings2(3%)
- Dividends2(3%)
- Other1(1%)
Latest news
25 items- PRPfizer Declares Second-Quarter 2026 DividendBoard of Directors approves quarterly cash dividend of $0.43 per share Pfizer Inc. (NYSE:PFE) today announced that its board of directors declared a $0.43 second-quarter 2026 dividend on the company's common stock, payable June 12, 2026, to holders of the Common Stock of record at the close of business on May 8, 2026. The second-quarter 2026 cash dividend will be the 350th consecutive quarterly dividend paid by Pfizer. About Pfizer: Breakthroughs That Change Patients' Lives At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, dev
- PRPfizer Showcases Oncology Innovation and Next-Generation Pipeline at ASCO 2026New evidence for established standard-of-care therapies, with updates for LORBRENA® in ALK-positive metastatic non‑small cell lung cancer and a BRAFTOVI® regimen in a type of BRAF-mutant colorectal cancer Extending potential impact of innovative therapies in earlier lines of treatment, including TALZENNA® plus XTANDI® in metastatic castration-sensitive prostate cancer and TUKYSA® as first-line maintenance for HER2-positive breast cancer New and updated data from next-generation pipeline of novel mechanisms and differentiated combinations across solid tumors, including sigvotatug vedotin, PF-08634404 and atirmociclib Pfizer Inc. (NYSE:PFE) will present new data across its diverse,
- PRU.S. FDA Grants Priority Review to sBLA for PADCEV™ + Keytruda® as Perioperative Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin EligibilitySubmission based on statistically significant event-free and overall survival data from the Phase 3 EV-304 trialBuilding on the existing indication in cisplatin-ineligible muscle-invasive bladder cancer (MIBC), if approved, this regimen would be the first and only perioperative treatment for patients with MIBC regardless of cisplatin eligibility, marking a potential new standard of care TOKYO and NEW YORK, April 20, 2026 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and Pfizer Inc. (NYSE:PFE) announced that the U.S. Food and Drug Administration (FDA) accepted for Priority Review a supplemental Biologics License Application (sBLA) for periopera
- INSIDERSEC Form 4 filed by Bourla Albert4 - PFIZER INC (0000078003) (Issuer)
- INSIDERSEC Form 4 filed by Bourla Albert4 - PFIZER INC (0000078003) (Issuer)
- INSIDERSEC Form 3 filed by new insider Hancock Dennis P3 - PFIZER INC (0000078003) (Issuer)
- PRPfizer Invites Shareholders to View and Listen to Webcast of April 23 Virtual 2026 Annual Meeting of ShareholdersPfizer Inc. (NYSE:PFE) announced today that its shareholders and the general public are invited to access its virtual 2026 Annual Meeting of Shareholders on Thursday, April 23, 2026, at 9:00 a.m. EDT. Shareholders can find information on accessing and registering for the virtual meeting at https://meetnow.global/PFE2026. On the day of the Annual Meeting, shareholders may begin logging into the virtual meeting platform at 8:45 a.m. EDT using either the control number found on their proxy card, voting instruction form or the notice that was previously received. Only shareholders who log into the meeting using a control number will have the ability to ask questions or vote during the live me
- PRTelix Strengthens Board with Additional Director AppointmentsMELBOURNE, Australia and INDIANAPOLIS, April 09, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, "Telix") today announces two additional Non-Executive Director (NED) appointments, effective May 11, 20261, as part of Board expansion and succession planning: Maria Rivas, MD is an experienced public company board director and S&P 100 senior pharmaceutical executive with more than 25 years' experience in late-stage clinical development, commercialization and governance leadership. Dr. Rivas currently serves on the board of directors of The Cooper Companies, Inc. (NASDAQ:COO), a medical technology company, and also served as an independent director for Medidata
- PRAI-Enhanced Robotics in Pharma Manufacturing Signals Major Efficiency, Margin Expansion OpportunitiesAUSTIN, Texas, April 07, 2026 (GLOBE NEWSWIRE) -- AINewsWire Editorial Coverage: Pharmaceutical manufacturing is undergoing a structural shift as regulators demand higher standards for contamination control, data integrity and operational traceability. The European Union's revised GMP Annex 1 emphasizes minimizing human intervention and implementing a comprehensive contamination control strategy, requiring manufacturers to assess and mitigate contamination risks across personnel, processes and environments. The guidance also promotes the use of barrier technologies and automation to reduce contamination risk, reflecting the widely recognized principle that personnel are a primary source of
- INSIDERSEC Form 4 filed by Bourla Albert4 - PFIZER INC (0000078003) (Issuer)
- INSIDERSEC Form 4 filed by Taraporevala Cyrus4 - PFIZER INC (0000078003) (Issuer)
- INSIDERSEC Form 4 filed by Smith James C4 - PFIZER INC (0000078003) (Issuer)
- INSIDERSEC Form 4 filed by Quincey James4 - PFIZER INC (0000078003) (Issuer)
- INSIDERSEC Form 4 filed by Echevarria Joseph4 - PFIZER INC (0000078003) (Issuer)
- INSIDERSEC Form 4 filed by Narayen Shantanu4 - PFIZER INC (0000078003) (Issuer)
- INSIDERSEC Form 4 filed by Buckley Mortimer J4 - PFIZER INC (0000078003) (Issuer)
- PRPfizer Invites Public to View and Listen to Webcast of May 5 Conference Call with AnalystsPfizer Inc. (NYSE:PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10:00 a.m. EDT on Tuesday, May 5, 2026. The purpose of the call is to provide an update on Pfizer's results, as reflected in the company's First Quarter 2026 Performance Report, to be issued that morning. To view and listen to the webcast and view the Performance Report, visit our web site at www.pfizer.com/investors. Information on accessing and registering for the webcast will be available at www.pfizer.com/investors beginning today. Participants are advised to register in advance of the conference call. You can also listen to the conference
- PRPfizer and Valneva Announce Lyme Disease Vaccine Candidate Demonstrates Strong Efficacy in Phase 3 VALOR TrialVaccine candidate PF-07307405 (LB6V) demonstrated more than 70% efficacy in preventing Lyme disease in individuals aged five years and above The investigational vaccine candidate was well tolerated with no safety concerns identified at time of analysis Overall, results strengthen confidence in the vaccine candidate and Pfizer is planning submissions to regulatory authorities Pfizer Inc. (NYSE:PFE) and Valneva SE (NASDAQ:VALN, PARIS:VLA) today announced topline results from the Phase 3 VALOR "Vaccine Against Lyme for Outdoor Recreationists" clinical trial (NCT05477524) of its investigational 6-valent OspA-based Lyme disease vaccine candidate PF-07307405 (LB6V, formerly known as VLA
- PRPfizer Recommends Shareholders Reject the Mini-Tender Offer by Tutanota LLCPfizer Inc. (NYSE:PFE) today announced that it has received notice of an unsolicited mini-tender offer by Tutanota LLC ("Tutanota") to purchase up to 1 million shares of Pfizer common stock at a price of $32.00 per share in cash. The offer price of $32.00 per share is conditioned on, among other things, the closing price per share of Pfizer common stock exceeding $32.00 per share on the last trading day before the offer expires. This means that unless this condition is waived by Tutanota, Pfizer shareholders who tender their shares in the offer will receive a below-market price. The offer states that as of the date of the offer, Tutanota expects to extend the offer until the market price of
- PRTALZENNA Plus XTANDI Significantly Improves Radiographic Progression-Free Survival in Metastatic Prostate CancerPrimary endpoint met in Phase 3 TALAPRO-3 study demonstrating a statistically significant and clinically meaningful reduction in risk of disease progression or death in HRR gene-mutated metastatic hormone sensitive prostate cancer Consistent rPFS efficacy benefit was observed in patients whose tumors harbored BRCA and non-BRCA HRR gene alterations Interim analysis showed a strong trend toward improvement in overall survival These results will be discussed with global health authorities to potentially expand TALZENNA indication in this earlier stage disease Pfizer Inc. (NYSE:PFE) today announced positive topline results from the Phase 3 TALAPRO-3 study of TALZENNA® (talazoparib)
- PRPfizer Announces Positive Topline Phase 2 Results for Next-Generation CDK4 Inhibitor, Atirmociclib, in Second-Line Metastatic Breast CancerPrimary endpoint met in first randomized Phase 2 study, FOURLIGHT-1, showing a 40% reduction in the risk of disease progression or death with manageable safety profile More than 90% of patients initiated atirmociclib within 3 months of prior CDK4/6 inhibitor therapy Results strengthen confidence in atirmociclib as a potential first-in-class, next-generation cell cycle inhibitor backbone for HR+, HER2- breast cancer and provide further support for development strategy in earlier lines of treatment Pfizer Inc. (NYSE:PFE) today announced positive topline results from the randomized Phase 2 FOURLIGHT-1 study evaluating atirmociclib in combination with fulvestrant, versus fulvestrant o
- INSIDERSEC Form 4 filed by Chairman & CEO Bourla Albert4 - PFIZER INC (0000078003) (Issuer)
- SECSEC Form DEFA14A filed by Pfizer Inc.DEFA14A - PFIZER INC (0000078003) (Filer)
- SECSEC Form DEF 14A filed by Pfizer Inc.DEF 14A - PFIZER INC (0000078003) (Filer)
- PRPfizer's Phase 2 Study of Trispecific Antibody Positive in Moderate to Severe Atopic DermatitisStudy met primary endpoint, demonstrating statistically significant increase in the percentage of participants achieving EASI-75 at Week 16 across all doses tested, compared to placebo Tilrekimig (PF-07275315) was well-tolerated with a favorable safety profile Tilrekimig has the potential to be a first-in-class, once-monthly trispecific antibody targeting interleukin-4 (IL-4), interleukin-13 (IL-13), and thymic stromal lymphopoietin (TSLP) for multiple chronic Type 2 (Th2) inflammatory conditions including atopic dermatitis, asthma, and chronic obstructive pulmonary disease (COPD) Based on encouraging results, Pfizer plans to accelerate tilrekimig to Phase 3 development, with a pi